ReviewAmerican journal of hematology2020
Treatment and disease-related complications in multiple myeloma: Implications for survivorship.
Review in American journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Prognosis of concurrent renal impairment at diagnosis of multiple myeloma: a systematic review.Annals of medicine · 2024Pooled it
- Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes.Annals of hematology · 2024Pooled it
- The effect of exercise interventions on quality of life in patients with multiple myeloma: a systematic review and meta-analysis of randomised controlled trials.Clinical and experimental medicine · 2023Pooled it
- Efficacy of exercise interventions in multiple myeloma: a systematic review and meta-analysis.Journal of cancer survivorship : research and practice · 2026Review
- A Case of Lytic Bone Lesions and Unexpected Laboratory Findings: Navigating Diagnostic Uncertainty.Cureus · 2026Article
- Systemic bone loss measured by routine CT is associated with increased pain, postural decompensation, and survival in multiple myeloma.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Article
- Identification of Needs of Patients with Multiple Myeloma: A Questionnaire-Based Study in Israeli Patients.Acta haematologica · 2026Article
- Nanomedicine-Based Strategies for Multiple Myeloma Therapy.International journal of nanomedicine · 2026Review
- Renal Outcomes Following Autologous Stem Cell Transplantation in Dialysis-Dependent Patients With Multiple Myeloma: A Single-Center Study From a Low- and Middle-Income Country.Case reports in hematology · 2026Article
- Acute kidney injury predicts mortality, sarcopenia and postoperative morbidity in myxofibrosarcoma patients undergoing surgical resection.World journal of surgical oncology · 2025Article
- Predictors of quality of life in multiple myeloma patients: a multi-centered cross-sectional study.BMC cancer · 2025Article
- [Development, reliability, and validity of a treatment-related quality of life scale for Chinese patients with multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Treatment Patterns, Goals, and Decision-Making Criteria for Second- and Third-Line Therapies for Multiple Myeloma in Germany.Advances in therapy · 2025Article
- Patient preferences for triple-class-exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study.Future oncology (London, England) · 2025Article
- Detection of potential complications in cancer survivors after chemotherapy and development of a regional care network: the PASCA feasibility study.Frontiers in medicine · 2025Article
- Patterns of multimorbidity in older adults with multiple myeloma: An analysis of SEER-Medicare.PloS one · 2025Article
- Healthcare Costs and Treatment Patterns of Triplet Therapies in Relapsed/Refractory Multiple Myeloma: Real World Evidence from Italy.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines.Annals of hematology · 2024Review
- The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma-a single-centre, qualitative service evaluation study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
New treatments have transformed multiple myeloma into a chronic disease. Hence, optimal management of treatment and disease-related complications remains a critical component of survivorship care. Survivorship care model in cancers requiring a fixed-duration therapy may not be applicable to myeloma, since patients are exposed to multiple lines of continuous therapy along the disease trajectory. The two most common therapy-related causes of death, which require special consideration, are infection and second cancers. Identifying patients at a high risk of toxicities will facilitate individualized treatment selection and designing clinical trials for protective strategies targeting those patients. For example, prophylactic antibiotic or immunoglobulin replacement can be tested for primary prevention of infections in high-risk patients. Long-term follow up of ongoing trials and epidemiologic data will help identify the nature and trajectory of rare toxicities with a long latency, such as secondary cancers. Patients who are frail, have persistent renal insufficiency, and refractory to multiple lines of therapy need special attention regarding treatment toxicity and quality of life. In this review, we discuss the incidence, risk-factors, and management of treatment and disease-related complications in myeloma, discuss knowledge gaps and research priorities in this area, and propose a survivorship care model to improve health-care delivery to a growing pool of myeloma survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.